Left-sided ulcerative colitis: True extent of disease and risk of pouchitis

Alkoraishi, Ahmed S.; Wolff, Bruce G.; Smyrk, Thomas C.

doi:10.1016/s0016-5085(03)81097-1

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk of pouchitis following IPAA is not related to the extent of UC or to chronic inflammation of the appendix. 139 Therapy is medical, provided that mechanical outlet obstruction has been ruled out.…”

Section: Pouchitismentioning

confidence: 99%

Update in Medical Therapy of Ulcerative Colitis

Katz

2005

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

Recent advances in the pathogenesis of ulcerative colitis recognize the interface of genetic susceptibility, environmental factors (eg, gut microflora), and an altered host's immune response. The meteoric evolution of new therapies designed to address these pathogenetic factors may lead to confusing and often confounding treatment programs. This review is designed to assist the practitioner when in [corrected] incorporating new or novel therapies into a treatment program. These decisions are based on new clinical trial data and the experience of seasoned gastroenterologists with established remedies. NEWER CONCEPTS AND THERAPIES IN UC 5-ADA-- 1. Remains drug of choice for induction and maintenance of remission in mild to moderate IC.1,2 2. Rare but increased incidence of renal disease exists but benefits outweigh risks.18-20 3. Chemoprevention of colorectal cancer in UC is promising and may be related to higher dose and a lessened degree of inflammation.29-36 4. Bioequivalence of all USA 5-ASA is established. Choice of a 5-ASA preparation is not dependent on superiority of a particular mesalamine.3 Phosphodiesterase Inhibitor (OPC-6525)37: preliminary data promising Immunomodulators 6MP/AZA 1. long-term effect not waning51 2. concerns over lymphoma voiced but overall benefits outweigh risks64-70 3. 6MP metabolites measurements of increasing use52-56 Cyclosporine experience continues but serious adverse events remains.105-114 Biologics Infliximab--somewhat disappointing in CUC, awaiting RCT87-92 Basiliximab--useful as "steroid sensitizer" in previously steroid resistant patients118-120 Visilizumab--promising as alternative to cyclosporin in server U.C.115-117 Apheresis--and emerging "non-drug" treatment alternative121-135 Probiotics--Useful in pouchitis and some mild to moderate U.C.94-98, 154 ISIS topical therapy useful in early pilot study (pouchitis)151 Budesonide (pouchitis)147 Antibiotics (pouchitis)140-146 [corrected]

show abstract

Section: Pouchitismentioning

confidence: 99%

Update in Medical Therapy of Ulcerative Colitis

Katz

2005

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

show abstract

Left-sided ulcerative colitis: True extent of disease and risk of pouchitis

Cited by 1 publication

References 0 publications

Update in Medical Therapy of Ulcerative Colitis

Update in Medical Therapy of Ulcerative Colitis

Contact Info

Product

Resources

About